

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION, RAPID SUSPENSION (ALBUMIN-BOUND) (SYHX2011G1) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Paclitaxel Protein-Bound Particles for Injectable Suspension, Rapid Suspension (Albumin-Bound) (SYHX2011G1) (the “**Product**”) developed by the Group has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.

Breast cancer is the most common malignant tumor among women globally, posing a serious threat to women’s health. Taxanes are the most commonly used and effective cytotoxic chemotherapeutic agents for the treatment of advanced breast cancer. They have been proven to offer more significant survival benefits compared to other types of chemotherapy drugs, whether used as monotherapy or in combination therapy. The Product is a new generation innovative nano-preparation developed using patented technology and has the potential to become the world’s first rapidly dissolving albumin-bound paclitaxel formulation.

The indication for this approved clinical trial is the treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. This clinical trial approval will further enrich the Group’s international product pipeline and enhance the Group’s international competitiveness.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 March 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.